<--- Back to Details
First PageDocument Content
Health / Kidney diseases / Organ failure / Chronic kidney disease / Medical prescription / Compliance / Medicine / Pharmacology / Pharmaceutical sciences
Date: 2006-11-06 09:02:10
Health
Kidney diseases
Organ failure
Chronic kidney disease
Medical prescription
Compliance
Medicine
Pharmacology
Pharmaceutical sciences

Adherence to angiotensin-converting enzyme inhibitors in incident chronic kidney disease patients Changchun Wang, MS1, Wendy St. Peter, PharmD, FCCP1,2, Jiannong Liu, PhD1, Frank Daniels, BS1, David Gilbertson, PhD1, All

Add to Reading List

Source URL: www.usrds.org

Download Document from Source Website

File Size: 109,01 KB

Share Document on Facebook

Similar Documents

Nematode sperm motility* Harold E. Smith§ National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda MD, USA  Table of Contents

Nematode sperm motility* Harold E. Smith§ National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda MD, USA Table of Contents

DocID: 1uVU8 - View Document

The C. elegans eggshell* Kathryn K. Stein1,2 and Andy Golden1,§ 1 Laboratory of Biochemistry and Genetics, National Institute of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, Marylan

The C. elegans eggshell* Kathryn K. Stein1,2 and Andy Golden1,§ 1 Laboratory of Biochemistry and Genetics, National Institute of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, Marylan

DocID: 1uoGh - View Document

International Scholarly Research Network ISRN Pediatrics Volume 2012, Article ID, 6 pages doi:Clinical Study

International Scholarly Research Network ISRN Pediatrics Volume 2012, Article ID, 6 pages doi:Clinical Study

DocID: 1rtjf - View Document

fs004:20 AM

fs004:20 AM

DocID: 1rhmX - View Document

Trust in excellence  Vifor Pharma, a company of the Galenica Group 2 Vifor Pharma

Trust in excellence Vifor Pharma, a company of the Galenica Group 2 Vifor Pharma

DocID: 1rciw - View Document